Skip to main content
Erschienen in: Journal of Infection and Chemotherapy 3/2012

01.06.2012 | Original Article

Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study

verfasst von: Koichiro Yoshida, Atsuyuki Kurashima, Katsuhiko Kamei, Masaru Oritsu, Tsunehiro Ando, Toshinori Yamamoto, Yoshihito Niki

Erschienen in: Journal of Infection and Chemotherapy | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

In the respiratory field, chronic pulmonary aspergillosis, such as chronic necrotizing pulmonary aspergillosis (CNPA) or aspergilloma, is important. We examined the efficacy and safety of short- and long-term itraconazole (ITCZ) administration, involving a switch from injection to an oral preparation, in patients with CNPA. In all hospitals participating in this study, the protocol was approved by the ethics review board. This study started after UMIN registration (UMIN000001727). Subjects enrolled in this study were patients who were clinically or definitively diagnosed with CNPA in the respiratory field, according to the diagnostic criteria of the Japanese “Guidelines for management of deep-seated mycosis 2007,” in 16 hospitals that participated in this study between May 2008 and March 2011. Treatment was started with ITCZ injection. Subsequently, the agent was switched to an oral preparation. Efficacy was evaluated with major items (clinical symptoms, fever, imaging findings) and minor items (nutritional status, inflammatory markers). Twenty-nine patients were enrolled; safety was evaluated in 24 and efficacy in 23. Of the 23 patients, 10 (43.5 %) responded. With respect to the administration period, the response rates in 8 patients treated for a short period and 15 treated for a long period were 25.0 % and 53.3 %, respectively. Trough blood concentration of ITCZ reached a level at which ITCZ may be effective for aspergillosis at 3 days after the start of ITCZ injection therapy. After changing to high-dose capsules, its level was also maintained. Adverse events such as liver dysfunction and heart failure were observed in 9 of the 24 patients. Furthermore, 6 patients died. However, there was no relationship between these events and ITCZ. Step-down therapy from ITCZ injection to oral administration may be a useful treatment option in CNPA patients requiring long-term treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nam H-S, Jeon K, Um S-W, Suh GY, Chung MP, Kim H, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14:e479–82.PubMedCrossRef Nam H-S, Jeon K, Um S-W, Suh GY, Chung MP, Kim H, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis. 2010;14:e479–82.PubMedCrossRef
2.
Zurück zum Zitat Deep-Seated Mycosis Guidelines Editorial Committee. Guidelines for management of deep-seated mycosis 2007 (in Japanese). Tokyo: Kyowakikaku; 2007. Deep-Seated Mycosis Guidelines Editorial Committee. Guidelines for management of deep-seated mycosis 2007 (in Japanese). Tokyo: Kyowakikaku; 2007.
3.
Zurück zum Zitat Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltim). 1982;61:109–24.CrossRef Binder RE, Faling LJ, Pugatch RD, Mahasaen C, Snider GL. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine (Baltim). 1982;61:109–24.CrossRef
4.
Zurück zum Zitat Oguchi K, Uchida E, Kobayashi S, Yasuhara H, Sakamoto K, Nagai T. Phase I study on itraconazole (ITZ), an oral triazole antifungal: pharmacokinetics of ITZ in healthy subjects after single and multiple oral administrations. Kiso to Rinsho. 1991;25:397–407. Oguchi K, Uchida E, Kobayashi S, Yasuhara H, Sakamoto K, Nagai T. Phase I study on itraconazole (ITZ), an oral triazole antifungal: pharmacokinetics of ITZ in healthy subjects after single and multiple oral administrations. Kiso to Rinsho. 1991;25:397–407.
5.
Zurück zum Zitat Uchida K, Matsuzaka A, Aoki K, Yamaguchi H. In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses. Jpn J Antibiot. 1991;44:562–70.PubMed Uchida K, Matsuzaka A, Aoki K, Yamaguchi H. In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses. Jpn J Antibiot. 1991;44:562–70.PubMed
6.
Zurück zum Zitat Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007;131:1435–41.PubMedCrossRef Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest. 2007;131:1435–41.PubMedCrossRef
7.
Zurück zum Zitat Hagiwara E, Sekine A, Sato T, Baba T, Shinohara T, Endo T, et al. Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease. J Jpn Respir Soc. 2008;46:864–9. Hagiwara E, Sekine A, Sato T, Baba T, Shinohara T, Endo T, et al. Clinical features of chronic necrotizing pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease. J Jpn Respir Soc. 2008;46:864–9.
8.
Zurück zum Zitat Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). J Infect. 2010;61:410–8.PubMedCrossRef Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. Japan Chronic Pulmonary Aspergillosis Study Group (JCPASG). J Infect. 2010;61:410–8.PubMedCrossRef
9.
Zurück zum Zitat Kohno S, Niki Y, Amitani R, Ogawa K, Kurashima A, Miyazaki Y. Clinical efficacy and safety of micafungin, a novel echinocandin antifungal drug, in pulmonary aspergillosis in a postmarketing setting. Jpn J Chemother. 2010;58:128–39. Kohno S, Niki Y, Amitani R, Ogawa K, Kurashima A, Miyazaki Y. Clinical efficacy and safety of micafungin, a novel echinocandin antifungal drug, in pulmonary aspergillosis in a postmarketing setting. Jpn J Chemother. 2010;58:128–39.
10.
Zurück zum Zitat Kohno S, Yamaguchi H, Mori T, Hirai H, Oritsu M, Niki Y, et al. Efficacy and safety of itraconazole injections and capsules in deep mycosis: uncontrolled multicenter open-label trial. Itraconazole-Deep Mycosis Research Group. Jpn J Chemother. 2006;54(Suppl 1):32–47. Kohno S, Yamaguchi H, Mori T, Hirai H, Oritsu M, Niki Y, et al. Efficacy and safety of itraconazole injections and capsules in deep mycosis: uncontrolled multicenter open-label trial. Itraconazole-Deep Mycosis Research Group. Jpn J Chemother. 2006;54(Suppl 1):32–47.
11.
Zurück zum Zitat Tomioka H, Ohnishi H, Tada K, Iwasaki H, Shinzato I, Yabe H, et al. Serum itraconazole concentrations in the treatment of pulmonary aspergillosis. Antibiot Chemother. 2007;23:147–53. Tomioka H, Ohnishi H, Tada K, Iwasaki H, Shinzato I, Yabe H, et al. Serum itraconazole concentrations in the treatment of pulmonary aspergillosis. Antibiot Chemother. 2007;23:147–53.
12.
Zurück zum Zitat Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IGH. Itraconazole trough concentration in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42:591–600.PubMedCrossRef Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IGH. Itraconazole trough concentration in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-β-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999;42:591–600.PubMedCrossRef
13.
Zurück zum Zitat Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135–44.PubMedCrossRef Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135–44.PubMedCrossRef
Metadaten
Titel
Efficacy and safety of short- and long-term treatment of itraconazole on chronic necrotizing pulmonary aspergillosis in multicenter study
verfasst von
Koichiro Yoshida
Atsuyuki Kurashima
Katsuhiko Kamei
Masaru Oritsu
Tsunehiro Ando
Toshinori Yamamoto
Yoshihito Niki
Publikationsdatum
01.06.2012
Verlag
Springer Japan
Erschienen in
Journal of Infection and Chemotherapy / Ausgabe 3/2012
Print ISSN: 1341-321X
Elektronische ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0414-7

Weitere Artikel der Ausgabe 3/2012

Journal of Infection and Chemotherapy 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.